DRMA Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
Cost of Revenue
0
0
0
0
0
Gross Profit
Operating Expenses
1.9M
+1.4%
1.9M
+7.9%
1.8M
-0.7%
1.8M
-24.2%
2.3M
R&D
383.7K
-27.1%
526.6K
+4.4%
504.4K
-18.4%
617.8K
-51.8%
1.3M
SG&A
1.5M
+12.3%
1.4M
+9.4%
1.3M
+8.8%
1.2M
+9.1%
1.1M
Operating Income
-1926382
-1.4%
-1900393
-7.9%
-1760671
+0.7%
-1772731
+24.2%
-2339803
EBITDA
-1926382
-1.4%
-1900393
-7.9%
-1760671
+0.7%
-1772731
+24.2%
-2339803
Net Income
-1847706
+0.8%
-1861888
-10.0%
-1691989
+0.5%
-1701093
+26.2%
-2303587
EPS (Basic)
$-0.48
+68.4%
$-1.52
+7.9%
$-1.65
+0.6%
$-1.66
+62.9%
$-4.47
EPS (Diluted)
$-0.48
+68.4%
$-1.52
+7.9%
$-1.65
+0.6%
$-1.66
+62.9%
$-4.47
Shares (Diluted)
3.9M
+316.6%
926.2K
-9.8%
1.0M
-0.0%
1.0M
+99.1%
515.5K
Dermata Therapeutics (DRMA) — Financials